Bill > H1617

Introduced Session

An act relating to stem cell therapy; creating ss. 458.3245 and 459.0127, F.S.; providing legislative intent; defining terms; authorizing allopathic physicians and osteopathic physicians to perform stem cell therapy not approved by the United States Food and Drug Administration under certain circumstances; specifying requirements for the stem cells that may be used by allopathic physicians and osteopathic physicians; requiring allopathic physicians and osteopathic physicians to adhere to applicable current good manufacturing practices in the performance of such therapies; prohibiting allopathic physicians and osteopathic physicians from obtaining stem cells for therapies from facilities failing to meet certain requirements; requiring allopathic physicians and osteopathic physicians to include certain terms in contracts or agreements with facilities producing stem cells for therapies; requiring allopathic physicians and osteopathic physicians to include a specified notice in any form of advertisement; providing requirements for such notice; requiring allopathic physicians and osteopathic physicians to obtain a signed consent form from the patient or his or her representative before performing the therapy; specifying requirements for the consent form; providing applicability; providing for disciplinary action; requiring the Board of Medicine and the Board of Osteopathic Medicine to adopt rules, respectively; providing an effective date.

Committee Categories

James Buchanan (R)*,  Dean Black (R), 

Other Sponsors (2)

Laid on Table, companion bill(s) passed, see CS/CS/SB 1768 (Ch. 2025-185) (on 04/30/2025)

Official Document